文献速递神经MR

钆对比剂对中央静脉征检出及诊断效能的影响:3-T FLAIR*序列在多发性硬化疑似患者中的评估

Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.
PubMed 文献 · AJR Am J Roentgenol · 2022-08-17

本研究为CAVS-MS前瞻性多中心预试验的二次分析,随机选取30例疑似MS患者,行3-T脑MRI包括FLAIR及增强前后T2*加权采集,生成FLAIR*图像。结果显示钆对比剂使用增加中央静脉征(CVS)检出,在40%阈值下CVS诊断MS的敏感度从增强前62%升至增强后92%,特异度无显著差异。

要点

  • 增强后FLAIR*可提高CVS检出率,从而提升MS诊断敏感度。
  • 40% CVS阳性阈值下,增强后敏感度92%,增强前62%。
  • 临床及未来试验中考虑使用增强后FLAIR*评估CVS。

核心结论

  • 钆对比剂使用增加了FLAIR*图像上CVS的检出,进而提高了CVS诊断MS的敏感度。

研究设计与样本

  • 研究为CAVS-MS前瞻性多中心预试验的二次分析,随机选取30例疑似MS成人患者(23女7男,平均45岁)。
  • 所有患者行3-T脑MRI包括FLAIR及增强前后回波平面T2*加权采集,后处理生成FLAIR*图像。
  • MS诊断依据2017 McDonald标准,由一名对临床及钆使用盲法的观察者评估白质病变的CVS。

关键影像表现/征象

  • 增强前FLAIR*上CVS阳性白质病变218个、阴性517个;增强后阳性269个、阴性459个。
  • MS患者增强前和增强后CVS阳性白质病变比例分别为48%和58%,非MS患者分别为7%和10%。
  • MS患者增强前和增强后患者水平CVS阳性率中位数分别为43%和67%,非MS患者分别为4%和8%。

诊断标准与关键数值

  • 在40% CVS阳性阈值下,CVS诊断MS的敏感度增强前为62%,增强后为92%(p=.046)。
  • 特异度增强前为88%,增强后为82%,两者无显著差异(p=.32)。
  • 调整MS诊断后,钆使用与至少一个CVS阳性白质病变的可能性增加相关(OR=1.6,p<.001)。

临床应用与阅片要点

  • 在临床实践中,对于疑似MS患者,可考虑使用增强后FLAIR*序列评估CVS以提高诊断敏感度。
  • 解读CVS时需注意钆对比剂可能增加CVS阳性病变数量,但特异度未显著降低。

局限性

  • 本研究为预试验的二次分析,样本量较小(30例),仅由单一观察者评估CVS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The central vein sign (CVS) is a proposed MRI biomarker of multiple sclerosis (MS). The impact of gadolinium-based contrast agent (GBCA) administration on CVS evaluation remains poorly investigated. OBJECTIVE. The purpose of this study was to assess the effect of GBCA use on CVS detection and on the diagnostic performance of the CVS for MS using a 3-T FLAIR* sequence. METHODS. This study was a secondary analysis of data from the pilot study for the prospective multicenter Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS), which recruited adults with suspected MS from April 2018 to February 2020. Participants underwent 3-T brain MRI including FLAIR and precontrast and post-contrast echo-planar imaging T2*-weighted acquisitions. Postprocessing was used to generate combined FLAIR and T2*-weighted images (hereafter, FLAIR*). MS diagnoses were established using the 2017 McDonald criteria. Thirty participants (23 women, seven men; mean age, 45 years) were randomly selected from the CAVS-MS pilot study cohort. White matter lesions (WMLs) were marked using FLAIR* images. A single observer, blinded to clinical data and GBCA use, reviewed marked WMLs on FLAIR* images for the presence of the CVS. RESULTS. Thirteen of 30 participants had MS. Across participants, on precontrast FLAIR* imaging, 218 CVS-positive and 517 CVS-negative WMLs were identified; on post-contrast FLAIR* imaging, 269 CVS-positive and 459 CVS-negative WMLs were identified. The fraction of WMLs that were CVS-positive on precontrast and postcontrast images was 48% and 58% in participants with MS and 7% and 10% in participants without MS, respectively. The median patient-level CVS-positivity rate on precontrast and postcontrast images was 43% and 67% for participants with MS and 4% and 8% for participants without MS, respectively. In a binomial model adjusting for MS diagnoses, GBCA use was associated with an increased likelihood of at least one CVS-positive WML (odds ratio, 1.6; p < .001). At a 40% CVS-positivity threshold, the sensitivity of the CVS for MS increased from 62% on precontrast images to 92% on postcontrast images (p = .046). Specificity was not significantly different between precontrast (88%) and postcontrast (82%) images (p = .32). CONCLUSION. GBCA use increased CVS detection on FLAIR* images, thereby increasing the sensitivity of the CVS for MS diagnoses. CLINICAL IMPACT. The postcontrast FLAIR* sequence should be considered for CVS evaluation in future investigational trials and clinical practice.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Daboul, O'Donnell, Cao, et al. Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis. AJR Am J Roentgenol. 2022. PMID: 35975888. doi:10.2214/AJR.22.27731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。